X4 Pharmaceuticals, Inc. Common Stock
Symbol: XFOR (NASDAQ)
3.53
▲ (4.44%) 0.150
Company Description:
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Key Stats
- Today's Open: $3.39
- Today's High: $3.65
- Today's Low: $3.365
- Today's Volume: 410.10K
- Yesterday Close: $3.38
- Yesterday High: $3.53
- Yesterday Low: $3.31
- Yesterday Volume: 194.81K
- Last Min Volume: 8
- Last Min High: $3.53
- Last Min Low: $3.53
- Last Min VWAP: $3.53
Company Profile
- Name: X4 Pharmaceuticals, Inc. Common Stock
- Website: https://www.x4pharma.com
- Listed Date: 2017-11-16
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0001501697
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $77.67M
- Round Lot: 100
- Outstanding Shares: 22.45M
- Asset Type: CS
RECENT FILINGS FOR XFOR
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-18 | 424B3 | View |
| 2025-09-17 | EFFECT | View |
| 2025-09-17 | 8-K | View |
| 2025-09-15 | SCHEDULE 13G | View |
| 2025-09-10 | S-3 | View |
| 2025-09-10 | S-8 | View |
| 2025-08-25 | D | View |
| 2025-08-25 | 8-K | View |
| 2025-08-20 | SCHEDULE 13G | View |
| 2025-08-19 | SCHEDULE 13G | View |
| 2025-08-18 | SCHEDULE 13G | View |
| 2025-08-18 | SCHEDULE 13D | View |
| 2025-08-15 | SCHEDULE 13D/A | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | 3 | View |
| 2025-08-14 | 3 | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | 3 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
Latest News on XFOR